StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for STAA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $32.00 | $32.07 | +0.22% | 1.4M |
| 05-18 | $31.95 | $32.31 | +1.13% | 1.1M |
| 05-19 | $32.05 | $32.60 | +1.72% | 0.8M |
| 05-20 | $32.37 | $33.05 | +2.10% | 0.7M |
| 05-21 | $33.00 | $32.79 | -0.64% | 1.2M |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2021 2021-07-02 | Q2 2021 2021-04-02 | Annual 2021 2021-01-01 | Q4 2020 2020-10-02 |
|---|---|---|---|---|
Revenue | $7.38M | $4.25M | $22.05M | $15.90M |
Operating Income | $18.12M | $7.47M | $6.77M | $2.69M |
Net Income | $13.56M | $4.99M | $5.91M | $3.89M |
EPS (Diluted) | $0.27 | $0.10 | $0.12 | $0.08 |
Total Assets | $294.44M | $265.81M | $257.42M | $234.70M |
Total Liabilities | $59.82M | $51.63M | $60.19M | $48.31M |
Cash & Equivalents | $173.08M | $162.34M | $152.45M | $128.34M |
Free Cash Flow OCF − CapEx | $7.46M | $4.61M | $12.55M | $-4.86M |
Shares Outstanding | 47.39M | 46.86M | 46.49M | 47.59M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.